Study summary

An anti-CD38 antibody quickly lowered the antibodies that cause membranous nephropathy

M-PLACE trial (felzartamab) · 31 people, phase 1b/2a · Published September 2024, Kidney International Reports

76.9%with at least a 50% drop in anti-PLA2R antibodies

What was tested

Felzartamab, an antibody against CD38 on antibody-making plasma cells, given in 9 infusions over 24 weeks, in high-risk anti-PLA2R-positive membranous nephropathy, including disease that resisted other drugs.

What they found

What it means

Led to the phase 3 PROMINENT trial against tacrolimus.

Kidney Int Rep, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.